Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)

Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population.

[1]  O. Arrieta,et al.  The use of electron microscopy for diagnosis of malignant pleural mesothelioma. , 2017, Journal of thoracic disease.

[2]  M. Berry,et al.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. , 2015, The Journal of surgical research.

[3]  N. Pavlakis,et al.  Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales , 2014, British Journal of Cancer.

[4]  O. Arrieta,et al.  A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma , 2014, Cancer Chemotherapy and Pharmacology.

[5]  G. Reid,et al.  An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma , 2013, British journal of cancer.

[6]  D. Henderson,et al.  Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. , 2013, Clinical lung cancer.

[7]  L. A. Medina,et al.  First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial , 2012, British Journal of Cancer.

[8]  M. Chatfield,et al.  Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Kotanidou,et al.  Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study , 2011, American journal of clinical oncology.

[10]  B. McCaughan,et al.  Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. , 2009, The Annals of thoracic surgery.

[11]  Ignacio Wistuba,et al.  Malignant Pleural Mesothelioma , 2017 .

[12]  A. Musk,et al.  Predicting survival in malignant mesothelioma , 2009, European Respiratory Journal.

[13]  Megu Ohtaki,et al.  Recent Mortality from Pleural Mesothelioma, Historical Patterns of Asbestos Use, and Adoption of Bans: A Global Assessment , 2008, Environmental health perspectives.

[14]  S. Lundgren,et al.  Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. , 2008, Lung cancer.

[15]  A. Nicholson,et al.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial , 2008, The Lancet.

[16]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Copin,et al.  Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.

[18]  J. Sørensen,et al.  Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Eisen,et al.  The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Pass,et al.  Malignant pleural mesothelioma. , 2004, Current problems in cancer.

[22]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Chevalier,et al.  Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[25]  T. Powles,et al.  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. , 2009, Lung cancer.

[26]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.

[28]  R. Shemin,et al.  Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.